THE BUSINESS OF LONGEVITY Chapter One From Stem Cells to Shareholders

How an Experimental Therapy Became an Investment Proposition

Introduction

Every investigation begins with a question.

Mine was simple.

Does Cell-Free Therapy work?

I expected months of reading scientific papers, analysing clinical evidence and speaking to researchers.

Instead, something unexpected happened.

The further I investigated Wellbeing International Foundation, the less this appeared to be solely a story about regenerative medicine.

Increasingly, it became a story about business.

About investment.

About capital.

About corporate growth.

That is not a criticism.

Many important medical breakthroughs have only reached patients because investors were willing to finance years of expensive research.

But when science and investment begin travelling together, one question becomes unavoidable.

Which one is leading the journey?

A Different Type of Announcement

Earlier this year, Wellbeing International Foundation announced that it had successfully closed the first tranche of its 2026 investment round.

On its own, that announcement is entirely unremarkable.

Biotechnology companies raise investment every day.

Research costs money.

Clinical expansion costs money.

Scientific innovation rarely happens without capital.

What made this announcement interesting was not the fact that money had been raised.

It was the information that wasn't disclosed.

Unlike many listed companies, Wellbeing did not reveal:

• how much capital had been raised;

• the valuation placed upon the business;

• the identities of investors;

• the type of securities issued;

• the ownership changes resulting from the investment.

Instead, the company explained that these details remained private and were handled by its legal and finance teams. That approach may be entirely appropriate for a privately held company, but it inevitably limits the amount of independent due diligence that outsiders can perform.

More Than a Medical Company?

As I continued examining Wellbeing's public material, another pattern began to emerge.

The organisation speaks not only about science, but also about:

• international expansion;

• research infrastructure;

• operational growth;

• strategic partnerships;

• clinical networks;

• investment.

This is no longer simply the language of a laboratory.

It is the language of a business with ambitions to grow.

Again, there is nothing improper about that.

The question is whether the commercial narrative is keeping pace with the scientific evidence—or running ahead of it.

The Importance of Peer Review

Only a short time after announcing its investment round, Wellbeing celebrated another significant milestone.

Its longevity programme had been published in a peer-reviewed scientific journal.

That matters.

Peer review is an important part of the scientific process.

It demonstrates that research has been scrutinised sufficiently to warrant publication.

It does not establish that a treatment has been clinically proven.

As explored in the previous chapter of this investigation, the published study was a small, company-linked pilot involving just fourteen participants and multiple simultaneous interventions.

The authors themselves acknowledged important limitations.

Nevertheless, publication transformed the company's position.

It could now accurately say that its programme had been the subject of peer-reviewed research.

From a commercial perspective, that is a powerful milestone.

A Name That Invites Questions

Another feature of the investigation deserves closer examination.

The organisation is called Wellbeing International Foundation.

To many members of the public, the word Foundation suggests a charitable, educational or philanthropic institution.

Yet the company's own public communications describe:

• patient revenue;

• private investment;

• commercial expansion;

• growth plans;

• capital raising.

That does not mean the name is misleading.

Many organisations combine commercial and research activities.

However, it does raise a reasonable question.

How is the organisation structured?

Which legal entities own the intellectual property?

Which entity receives patient income?

Which entity issued the investment?

Those questions are central to understanding the business.

The Bermuda Structure

Wellbeing states that it is headquartered in Bermuda.

Bermuda is a respected international financial centre and is home to many legitimate global businesses.

Equally, privately held companies incorporated there are generally subject to different public disclosure requirements from companies listed on major stock exchanges.

That does not imply secrecy or wrongdoing.

But it does mean that prospective patients, journalists and investors may find considerably less publicly available financial information than they would expect from a listed company. This can make independent assessment more challenging.

Science, Investment and Trust

Medical innovation needs investment.

Without investors, many life-changing treatments would never progress beyond the laboratory.

Investment itself is not the issue.

Transparency is.

Patients place trust in science.

Investors place trust in management.

Both groups deserve sufficient information to make informed decisions.

That principle becomes especially important when scientific evidence remains at an early stage of development.

The Investigation Changes Direction

When this series began, I thought I was investigating regenerative medicine.

Today, I believe I am investigating something larger.

The commercialisation of longevity.

The intersection where emerging science meets private capital.

The point at which medical promise becomes an investment proposition.

That journey is not unique to Wellbeing.

It is happening throughout the global longevity industry.

Understanding how those businesses are financed may ultimately prove just as important as understanding the science they promote.

Next Chapter

Every company has a public face.

Every chairman has a biography.

In the next chapter, we begin examining the corporate history of one of the key figures behind Wellbeing International Foundation.

Not through opinion.

Not through rumour.

But through company records, court judgments, insolvency documents and other primary sources.

Because in any investigation, the documents tell the story.